Autosomal Dominant Polycystic Kidney Disease ADPKD

Cystic Kidney Disease

Chronic Kidney Disease

MyelomaRelated Kidney Disease

Medullary cystic kidney disease

Tolvaptan improves kidney health in polycystic kidney disease

A vasopressin V2-receptor blocker slows the increase in total kidney volume and decline in kidney function in patients with autosomal dominant polycystic kidney disease, report US researchers.

Tolvaptan: How Good Is It for Polycystic Kidney Disease?

Jeffrey Berns comments on the results presented at ASN 2012 on the effect of tolvaptan on autosomal dominant polycystic kidney disease. Medscape Nephrology

Tolvaptan: Exciting Progress for Polycystic Kidney Disease

In this international Skype conversation, Lynda Szczech and Donal O’Donoghue provide in-depth guidance on the current research and use of tolvaptan in autosomal dominant polycystic kidney disease....

Take the PKD Foundation Challenge

By Jill Panetta, Chief Scientific Officer, PKD Foundation Polycystic Kidney Disease (PKD) Awareness Week has been designated the week of June 18 to 24, 2012.  This week allows the PKD Foundation to b...

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

A drug therapy shows promise for treating an inherited form of kidney disease called autosomal dominant polycystic kidney disease (ADPKD), Mayo Clinic researchers say.

New approaches in treating complicated childhood polycystic kidney disease

(Medical College of Wisconsin) A collaborative team of physician-scientists at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute has developed a new evidence-bas...

Polycystic kidney disease: Polycystin-1 and polycystin-2—it's complicated

Mutations in the genes that encode polycystin-1 and polycystin-2 are the principal cause of autosomal dominant polycystic kidney disease. These proteins form a receptor–ion-channel complex and were...

Hyponatremia Tx Slows Kidney Disease Progress (CME/CE)

SAN DIEGO (MedPage Today) -- A vasopressin receptor antagonist slowed both the rise in kidney volume and the decline in kidney function in patients with autosomal dominant polycystic kidney disease (A...

Polycystic kidney disease: Promising new potential therapies for patients with autosomal dominant polycystic kidney disease.

Polycystic kidney disease in 2011: Connecting the dots toward a polycystic kidney disease therapy.

Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

To the Editor: In the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcome (TEMPO) 3:4 trial, Torres et al. (Dec. 20 issue)(1) found that tolvapt...

Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

To the Editor: In the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcome (TEMPO) 3:4 trial, Torres et al. (Dec. 20 issue)(1) found that tolvapt...

Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

To the Editor: In the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcome (TEMPO) 3:4 trial, Torres et al. (Dec. 20 issue)(1) found that tolvapt...